ENA Respiratory is a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for the prophylaxis of respiratory viral infections, including COVID-19, rhinovirus and influenza in populations at risk of complications. The company is based in Melbourne, Australia and it has secured a Series A investment from the Brandon Capital Partners' managed funds, the Minderoo Foundation and Uniseed. In early 2022, ENA Respiratory was the first company in the Asia Pacific region to join Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and BARDA. The company also established in 2022 a strategic partnership with the US COPD foundation. In December 2022, the company was awarded a USD4.38M grant from the United States Department of Defense to further support the development of its lead asset, INNA-051.